Donald Trump Jr. allegedly stands to reap handsome profits from his dad’s radical overhaul of the way consumers purchase pharmaceutical drugs.
BlinkRx, a company specializing in the online order and delivery of prescription drugs, appointed the younger member of the Trump clan to its board earlier in February, the Wall Street Journal reported Tuesday.
Given its business model, BlinkRx is one of a number of companies set to benefit from the MAGA administration’s mounting push for pharmaceutical manufacturers to begin selling drugs directly to patients, rather than through middlemen otherwise known as “pharmacy benefit managers,” the newspaper adds.
The post Trump’s Drug Overhaul Set to Line Relative’s Pockets appeared first on The Daily Beast